Photo-recall cutaneous reaction to gemcitabine

Simone D'Adamio, Marina Talamonti, Luca Bianchi, Marco Galluzzo

Abstract


Cutaneous reactions attributable to chemotherapy too often result in a modification of patients’ treatment plan. Most treatments remain largely unproven: only small series or case reports may indicate possible treatment options. Main observations: We reported the case of a male patient with gemcitabine-induced skin reaction occurred after a cycle of therapy with carboplatin plus gemcitabine following a 21 days’ schedule. The patient came to our attention for an extensive, well-demarked, erythematous, lilaceous, warm indurated lesion, covering his dorsal faces of both hands, without systemic symptoms. Clobetasol propionate 0.05% ointment was prescribed as main therapy, followed by a cream containing boswellic acids. Conclusions: It is presumable that similar dermatological lesions consist in a ‘radiation recall reaction’ whereby an inflammatory reaction occurs in the area previously treated with radiotherapy or affected by a sun-burn in the past. In our patient, interestingly, there is no history of radiotherapy even if there is history of strong sun exposure. Pharmacological anti-inflammatory effect due to boswellic acids was studied and relieved only in radiation-induced dermatitis, and even if larger studies would have been set in order to have more effective results, it would be useful to study application of this compound in chemotherapy-induced cutaneous adverse reactions too.

Keywords


gemcitabine; chemotherapy-related skin toxicity; photo-recall skin reaction; boswelic acids

Full Text:

PDF

References


Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 2008; 26:103-119.

Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006; 7(1):45-63.

Sederholm C, Hillerdal G, Lamberg K. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23(33):8380-8388.

Yuh YJ, Lee HR, Kim SR. Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced non-small cell lung cancer: a feasibility study. Cancer Res Treat 2008; 40(3):116-120.

Kuku I, Kaya E, Sevinc A, et al. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma J Eur Acad Dermatol Venereol 2002; 16:271-272.

Tan DH, Bunce PE, Liles WC, et al. Gemcitabine-related “pseudocellulitis”: report of 2 cases and review of the literature. Clin Infect Dis 2007; 45:e72–76.

Togni S, Maramaldi G, Bonetta A, et al. Clinical evaluation of safety and efficacy of Boswellia -based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. Eur Rev Med Pharmacol Sci 2015; 19(8):1338-1344.

Brandes A, Reichmann U, Plasswilm L, et al. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine - a report of three cases. Anticancer Drugs 2000; 11(1):15-17.

Korniyenko A, Lozada J, Ranade A, et al. Recurrent lower extremity pseudocellulitis. Am J Ther 2012; 19(4):e141-142.

Zustovich F, Pavei P, Cartei G. Erysipeloid skin toxicity induced by gemcitabine. J Eur Acad Dermatol Venereol 2006; 20(6):757-758.

Ruiz-Casado A, Gutiérrez D, Juez I. Erysipeloid rash: A rare adverse event induced by gemcitabine. J Cancer Res Ther 2015; 11(4):1024.

Tan E: Skin toxicity of chemotherapy drugs [https://www.dermnetnz.org/topics/skin-toxicity-of-chemotherapy-drugs/#4 available at 12.26.2017].




DOI: http://dx.doi.org/10.22551/2017.17.0404.10113

Copyright (c) 2017 Simone D'Adamio, Marina Talamonti, Luca Bianchi, Marco Galluzzo

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975